Physician profile
John M Wright
NPI 1679550503
$8,808.51
in general payments reported to CMS, 2019-2025
44 companies · $837 in 2025
The $837 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,747 · 2020: $366 · 2021: $829 · 2022: $1,312 · 2023: $1,781 · 2024: $1,938 · 2025: $837.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,439 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,438.94 |
| Education | $115.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,610.69 | 2021-2025 | Qulipta, Ubrelvy |
| Jazz Pharmaceuticals INC. | $904.01 | 2019-2025 | |
| Tg Therapeutics, INC. | $682.45 | 2023-2025 | |
| Biogen, INC. | $676.26 | 2019-2025 | Vumerity, Tysabri |
| Novartis Pharmaceuticals Corporation | $598.31 | 2019 | |
| Harmony Biosciences LLC | $574.48 | 2020-2025 | Wakix |
| Itamar Medical INC | $389.09 | 2022-2025 | Watchpatone |
| Lilly USA, LLC | $311.37 | 2019-2025 | Kisunla, Amyvid, Zepbound |
| Janssen Pharmaceuticals, INC | $307.53 | 2021-2022 | |
| Lundbeck LLC | $224.37 | 2022-2025 | Vyepti |
| Axsome Therapeutics, INC. | $200.44 | 2022-2024 | Sunosi |
| Genzyme Corporation | $188.18 | 2019-2021 | |
| Genentech USA, INC. | $177.23 | 2021 | |
| Sk Life Science, INC. | $162.50 | 2021-2024 | |
| Mdd US Operations, LLC | $154.80 | 2019 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.